VANCOUVER, Canada--(BUSINESS WIRE)--Ondine Biomedical Inc. (LON: OBI) presented detailed results from its US Phase 2 BENEFIT-aPDT clinical trial to the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark. The results indicate that patients who underwent Ondine’s nasal photodisinfection prior to surgery experienced 66% fewer surgical site infections (SSIs) than the US national average. The Centers for Disease Control and Prevention (CDC) estimates that over 110,000 SSIs occur in the US each year, costing the healthcare system approximately $3.3 billion.2
Moreover, the study results showed that Ondine’s nasal photodisinfection eliminated or significantly reduced Staphylococcus aureus, including MRSA, in 88% of carriers immediately after treatment. Of the 313 patients who underwent the treatment prior to surgery, 21% were found to have S. aureus colonization in their nose. The nose is a well-known reservoir of infection-causing pathogens.3
S. aureus, including MRSA, is a major contributor to SSIs, and nasal decolonization has proven to be highly effective in preventing SSIs by eradicating S. aureus. SSIs are responsible for most hospital readmissions following surgery and are a significant cause of post-surgical morbidity and mortality, increasing the risk of mortality by 2- to 11-fold.4 A patient who develops an SSI will spend an average of five additional days in hospital,5 significantly increasing their recovery time and costs.
All patients in the study were treated with a single, 5-minute treatment of Ondine’s nasal photodisinfection, which eliminates infection-causing bacteria, viruses and fungi in the nose. Ondine’s nasal photodisinfection is a patented technology which uses a proprietary, non-antibiotic photosensitizer to destroy pathogens. When illuminated with a specific wavelength of light, the photosensitizer is activated, causing an oxidative burst that is lethal to all types of pathogens.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
4 Ban KA, Minei JP, Laronga C, et al. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. J Am Coll Surg. 2017;224(1):59-74. doi:10.1016/j.jamcollsurg.2016.10.029.
5 Shepard J, Ward W, Milstone A, et al. Financial Impact of Surgical Site Infections on Hospitals: The Hospital Management Perspective. JAMA Surg. 2013;148(10):907–914. doi:10.1001/jamasurg.2013.2246